mepenzolate bromide (cantil) Report issue

Small molecule Approved FDA
ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Mepenzolate is a postganglionic parasympathetic inhibitor. It decreases gastric acid and pepsin secretion and suppresses spontaneous contractions of the colon. It specifically antagonizes muscarinic receptors. Mepenzolate is marketed under the brand name CANTIL. CANTIL is indicated for use as adjunctive therapy in the treatment of peptic ulcer. It has not been shown to be effective in contributing to the healing of peptic ulcer, decreasing the rate of recurrence, or preventing complications.   NCATS

Chemistry

  • SMILES: C[N+]1(C)CCCC(C1)OC(=O)C(O)(c2ccccc2)c3ccccc3
  • InChIKey: GKNPSSNBBWDAGH-UHFFFAOYSA-N
  • Mol. Mass: 340.44
  • ALogP: 2.7
  • ChEMBL Molecules:
    mepenzolate  
    mepenzolate bromide  
More Chemistry

Pharmacology

Alternative names

aventis behring brand of mepenzolate bromide | cantil | glycophenylate | mepenzolate | mepenzolate bromide | mepenzolate bromide, (+-)-isomer | mepenzolate iodide | mepenzolate methylbromide | mepenzolic acid | mepenzolic acid, bromine salt | mepenzolic acid, bromine salt, 1-(methyl-(14)c)-labeled | mepenzolon | mepenzolone bromide | n-methyl-3-piperidylbenzilate methyl bromide

Organizations (1)

Research & Development (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (2)

Approved Indications (2)


 

Irritable Bowel Syndrome

Peptic Ulcer (approved 1956)

Experimental Indications - Clinical Trial Phases 1-4 (0)

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue